Progestogens for Prevention of Preterm Birth
Summary of Benefits: Effect of Formulation and Route of Administration
All formulations succeeded in reducing the risk for preterm birth, and no formulation was effective at reducing the risk for neonatal mortality. However, the evidence is insufficient to support conclusions about the true effect sizes. It is possible that differences associated with progestogen use arise solely from populations studied or other biases. Head-to-head comparisons are needed to provide sufficient evidence to permit conclusions about the comparative effectiveness of formulations.
Keywords: preterm birth | progesterone | progestogens | progestins | formulation | route of administration | 37 weeks | fetal mortality | neonatal mortality
- Likis FE, Andrews JC, Woodworth AL, et al. Effectiveness of Progestogens for Prevention of Preterm Birth. Comparative Effectiveness Review No. 74 (Prepared by the Vanderbilt Evidence-based Practice Center under Contract No. 290-2007-10065-I). Rockville, MD: Agency for Healthcare Research and Quality; September 2012. AHRQ Publication No. 12-EHC105-EF. Available at www.effectivehealthcare.ahrq.gov/pretermbirth.cfm.
Your slide tray is being processed.